Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Experimental Pain Trial of Karuna-Xanomeline-Trospium (KarXT) in Healthy Volunteers

Trial Profile

A Phase 1b Experimental Pain Trial of Karuna-Xanomeline-Trospium (KarXT) in Healthy Volunteers

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 02 Nov 2023 According to a Karuna Therapeutics media release, topline data expected in the fourth quarter of 2023.
  • 03 Aug 2020 According to a Karuna Therapeutics media release, topline results of this exploratory trial were inconclusive and do not provide sufficient evidence of an analgesic benefit of KarXT compared to placebo. The Company will not move forward to develop KarXT in pain.
  • 03 Aug 2020 According to a Karuna Therapeutics media release, the company will continue to evaluate data from this trial to better assess the potential role of muscarinic-targeted receptor treatments in pain management.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top